RGNX Stock — REGENXBIO Inc.: Cash, EV, Pipeline

What they do

We are a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our investigational gene therapies are designed to deliver functional genes to address genetic defects in cells, enabling the production of therapeutic proteins or antibodies that are intended to impact disease.

Source: 10-K FY2025 via SEC EDGAR

Share price

$7.65

Market cap

$505.7M

Cash

$251.0M

Enterprise value

$440.4M

Balance sheet

Cash	$251.0M
Debt	$0.0M
Royalty-sale liability	$185.7M
Net cash	$251.0M
Enterprise value	$440.4M
Basic shares	66.1M shares
Fully diluted shares	67.2M shares
Fully diluted market cap	$513.8M
Cash per share	$3.80
Quarterly burn	$62.2M
Cash runway	4.0 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-13.

Royalty-sale liability as of 2026-09-30 (10-Q); included in enterprise value.

Share structure

Common

66.0M

Pre-funded warrants

0.0M

Options

0.0M

RSUs

0.0M

Warrants

1.1M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

67.2M

Cap table as of 2026-06-30.

Price history

Loading RGNX daily closes…

Loading price history…

Next catalyst

Aflibercept (EYLEA®) · Now - Dec 24, 2026 Now · Phase 3 · AMD; nAMD; Wet Age-related Macular Degeneration

Recently reported

surabgene lomparvovec (sura-vec) Phase 2 Positive · 2026-09-24

ABBV-RGX-314 · diabetic retinopathy (dr), center-involved diabetic macular edema (ci-dme)

Source release →

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Dec 24, 2026 Now	Aflibercept (EYLEA®)	Phase 3	AMD; nAMD; Wet Age-related Macular Degeneration	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
Jan 12 - Feb 23 in 8 wks	Ranibizumab (LUCENTIS®)	Phase 3	AMD; nAMD; Wet Age-related Macular Degeneration	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
GUIDEDEst. Sep 30, 2027 in 8 mo half midpoint	RGX-202 RGX-202 potential approval under accelerated approval	Not disclosed	RGX-202 potential under accelerated	2H 2027
Jun 11 - Jul 23 in 19 mo	RGX-121-3102	Phase 3	MPS II; Hunter Syndrome (MPS II)	—
Jul 13 - Aug 24 in 57 mo	Standard of Care	Phase 2	Diabetic Retinopathy, DR	—
Aug 12 - Sep 23 in 58 mo	Standard of Care	Phase 2	Neovascular Age-Related Macular Degeneration (nAMD)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

ABBV-RGX-314

Phase 2/3 · Active Modality: gene therapy (AAV vector, NAV Technology Platform)

Aliases surabgene lomparvovec, sura-vec

Target VEGF

Partnerships AbbVie (collaboration to develop and commercialize ABBV-RGX-314)

Indications

Wet age-related macular degeneration (wet AMD) (Stage not disclosed)
Diabetic retinopathy (DR) (Phase 2/3)

Status note Lead product candidate developed with AbbVie. First patient dosed in the Phase 2b/3 diabetic retinopathy trial (NAAVIGATE) June 2026. Multiple wet AMD trials ongoing including AAVIATE, ALTITUDE, ASCENT and ATMOSPHERE.

RGX-121

Phase 3 · Active Modality: gene therapy (AAV vector, NAV Technology Platform)

Aliases clemidsogene lanparvovec

Target iduronate-2-sulfatase (IDS)

Partnerships Nippon Shinyaku (collaboration for development and commercialization; double-digit royalties on net sales in licensed territories)

Indications

Mucopolysaccharidosis Type II (MPS II) (Stage not disclosed)

Status note FDA Complete Response Letter received February 2026; planned BLA resubmission. Company retains rights to any priority review voucher upon approval.

RGX-111

Stage not disclosed · Active Modality: gene therapy (AAV vector, NAV Technology Platform)

Target IDUA

Partnerships Nippon Shinyaku (collaboration for development and commercialization)

Indications

Mucopolysaccharidosis Type I (MPS I) (Stage not disclosed)

Status note FDA imposed a clinical hold on the RGX-111 program January 28, 2026. Company retains rights to any priority review voucher upon approval.

RGX-202

Stage not disclosed · Active Modality: gene therapy (AAV vector, NAV Technology Platform)

Target microdystrophin

Indications

Duchenne muscular dystrophy (Stage not disclosed)

Status note Internal lead candidate for Duchenne; AFFINITY DUCHENNE trial ongoing.

Zolgensma (royalty interest)

Approved · Active

Target SMN1 (AAV9 gene replacement)

Partnerships Novartis (NAV Technology license)

Indications

Spinal muscular atrophy (SMA), pediatric (IV gene replacement) (Approved)

Status note Commercial product developed by NAV Technology Licensee; company receives royalties on net sales.

Itvisma (royalty interest)

Approved · Active

Target SMN1 (AAV9 gene replacement)

Partnerships Novartis (NAV Technology license)

Indications

Spinal muscular atrophy (SMA), children 2+ / teens / adults (intrathecal gene replacement) (Approved)

Status note Commercial product developed by NAV Technology Licensee; company receives royalties on net sales.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	RGX-121
Lead indication	Mucopolysaccharidosis Type II (MPS II)
Lead phase	Phase 3
Active trials	7
Collaborator trials	7

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07236606	Phase 3	Active, not recruiting	Sponsor	RGNX	—	MPS II; Hunter Syndrome (MPS II)	—
NCT03566043	Phase 3	Active, not recruiting	Sponsor	RGNX	—	Mucopolysaccharidosis Type II (MPS II)	—
NCT05693142	Phase 3	Active, not recruiting	Sponsor	RGNX	—	Duchenne Muscular Dystrophy	2H 2027 Est. Sep 30, 2027 · half midpoint
NCT06103487	Not disclosed	Enrolling by invitation	Sponsor	RGNX	—	Mucopolysaccharidosis I	—
NCT04597385	Not disclosed	Active, not recruiting	Sponsor	RGNX	—	Mucopolysaccharidosis II	Q3 2026
NCT06491927	Not disclosed	Enrolling by invitation	Sponsor	RGNX	—	Duchenne Muscular Dystrophy	Q3 2026 2H 2027 Est. Dec 31, 2027 · PCD + 6 wks (Dec 31-Dec 31)
NCT05683379	Not disclosed	Active, not recruiting	Sponsor	RGNX	—	Duchenne Muscular Dystrophy	—
NCT05407636	Phase 3	Active, not recruiting	Collaborator	ABBV	ABBV	AMD; nAMD; Wet Age-related Macular Degeneration	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT04704921	Phase 3	Active, not recruiting	Collaborator	ABBV	ABBV	AMD; nAMD; Wet Age-related Macular Degeneration	Q4 2026 Est. Nov 15, 2026 · quarter midpoint
NCT06942520	Phase 2	Recruiting	Collaborator	Sierra Eye Associates	—	Diabetic Macular Edema	—
NCT05296447	Phase 2	Enrolling by invitation	Collaborator	ABBV	ABBV	Diabetic Retinopathy, DR	—
NCT05210803	Phase 2	Enrolling by invitation	Collaborator	ABBV	ABBV	Neovascular Age-Related Macular Degeneration (nAMD)	—

Sponsor-matched active trials from ClinicalTrials.gov (7 as sponsor, 7 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 14 active trials for REGENXBIO Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Boxer Capital	15,000	no change	0.01%	2026-08-14
ADAR1 Capital Management	0	-44,416	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

RGNX — REGENXBIO Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Recently reported

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

RGNX — REGENXBIO Inc.